13345-50-1

Basic information

• Product Name: PROSTAGLANDIN A2
• Synonyms: PROSTAGLANDIN A2;PROSTA-5,10,13-TRIEN-1-OIC ACID, 15-HYDROXY-9-OXO-, (5Z,13E,15S);PROSTAGLANDINS A2;PGA2;(+)-prostaglandina(sup2);(155)-pga2;15-hydroxy-9-oxo-,(5z,13e,15s)-prosta-10-13-trien-1-oicacid;5,6-cis-pga(sup2)
• CAS NO: 13345-50-1
• Molecular Formula: C₂₀H₃₀O₄
• Molecular Weight: 334.45
• EINECS: 234-237-8
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 13345-50-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 391.24°C (rough estimate)
• Flash Point: -9 °C
• Appearance: /
• Density: 1.0332 (rough estimate)
• Vapor Pressure: 8.93E-13mmHg at 25°C
• Refractive Index: 1.4434 (estimate)
• Storage Temp.: −20°C
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly), Water (Slightly)
• PKA: 4.75±0.10(Predicted)
• CAS DataBase Reference: PROSTAGLANDIN A2(CAS DataBase Reference)
• NIST Chemistry Reference: PROSTAGLANDIN A2(13345-50-1)
• EPA Substance Registry System: PROSTAGLANDIN A2(13345-50-1)

Safety Data

• Hazard Codes: F,Xi
• Statements: 11-36-66-67
• Safety Statements: 26-16
• RIDADR: UN 1231 3/PG 2
• WGK Germany: 3
• F: 8-10
• Hazardous Substances Data: 13345-50-1(Hazardous Substances Data)

Usage

Description

Prostaglandin A2, a naturally occurring prostaglandin found in gorgonian corals, is known for its potential role in self-defense mechanisms. It is not typically present in mammals and exhibits low biological potency in most bioassays. However, it has been identified for its antiviral and antitumor activities, as well as its vasodilatory and natriuretic properties.

Uses

Used in Pharmaceutical Industry:
Prostaglandin A2 is used as a therapeutic agent for its antiviral and antitumor properties, making it a potential candidate for the development of treatments targeting various types of cancer and viral infections.
Used in Cardiovascular Applications:
In the field of cardiovascular medicine, Prostaglandin A2 is used as a vasodilator to help relax blood vessels, improving blood flow and reducing blood pressure. Its natriuretic properties also contribute to the regulation of fluid balance in the body, which can be beneficial for patients with heart-related conditions.
Used in Research and Development:
Due to its unique biological activities, Prostaglandin A2 is utilized in research and development for the study of its potential applications in various fields, including pharmacology, virology, and oncology. This can lead to the discovery of new drugs and therapies based on its properties and mechanisms of action.

InChI:InChI=1/C20H30O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h4,7,12-18,21H,2-3,5-6,8-11H2,1H3,(H,23,24)/b7-4-,14-12+/t16-,17-,18+/m0/s1

Upstream product

• 59193-92-9 (Z)-7-{(1R,2R)-2-[(E)-(S)-3-(1-Ethoxy-ethoxy)-oct-1-enyl]-5-oxo-cyclopentyl}-hept-5-enoic acid 
• 363-24-6 dinoprostone 
• 129944-69-0 (Z)-7-{(1R,2S)-2-[(E)-(S)-3-(tert-Butyl-diphenyl-silanyloxy)-oct-1-enyl]-5-oxo-cyclopent-3-enyl}-hept-5-enoic acid 
• 41100-77-0 dehydro PCA methyl ester 
• 85548-85-2 Bis(tert-butyldimethylsilyl)-PGE₂ oxime 
• 108-05-4 vinyl acetate 
• 2146-71-6 vinyl laurate 
• 85453-75-4 (Z)-7-[(1S,2S,3R,5S)-1-Benzenesulfonyl-3-(tert-butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-(2-hydroxy-2-methyl-propylamino)-cyclopentyl]-hept-5-enoic acid 
• 85548-87-4 (Z)-7-{(1S,2S,3R,5S)-1-Benzenesulfonyl-3-(tert-butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-methylamino-cyclopentyl}-hept-5-enoic acid methyl ester 
• 77494-47-4 Methyl (5Z,13E,8R,9S,11R,12S,15S)-11,15-Bis(tert-butyldimethylsiloxy)-9-(methylamino)-8-(phenylsulfonyl)-5,13-prostadienoate 
• 85548-77-2 Methyl (5Z,13E,8S,9S,11R,12S,15S)-11,15-Bis(tert-butyldimethylsiloxy)-9-(dimethylamino)-8-(phenylsulfonyl)-5,13-prostadienoate 
• 77506-98-0 Methyl (5Z,13E,8R,9S,11R,12S,15S)-11,15-Bis(tert-butyldimethylsiloxy)-9-(dimethylamino)-8-(phenylsulfonyl)-5,13-prostadienoate 
• 85610-69-1 (Z)-7-{(1S,2S,3R)-1-Benzenesulfonyl-3-(tert-butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-[(E)-hydroxyimino]-cyclopentyl}-hept-5-enoic acid 
• 85548-84-1 (5Z,13E,8R,11R,12S,15S)-11,15-Bis(tert-butyldimethylsiloxy)-9-(anti-oximino)-8-(phenylsulfonyl)-5,13-prostadienoic acid 

Downstream Products

• 55987-36-5 Prostaglandin A⁽²⁾-p-phenylbenzylester 
• 55931-12-9 (Z)-7-[(1R,2S)-2-((E)-(S)-3-Hydroxy-oct-1-enyl)-5-oxo-cyclopent-3-enyl]-hept-5-enoic acid biphenyl-4-yloxycarbonylmethyl ester 
• 55930-90-0 Prostaglandin A⁽²⁾-p-phenylphenacylester 
• 31753-19-2 (5Z,13E)-15-hydroxy-9-oxoprosta 5,10,13 trien-1-oic acid 
• 13367-85-6 prostaglandin B₂ 
• 33854-16-9 (+)-prostaglandin F_2α 
• 551-11-1 dinoprost 
• 53122-04-6 15α-O-t-butyldimethylsilyl-PGA₂ methyl ester 
• 87692-41-9 5,6-dihydro-5,6-dihydroxy-PGF_2α 
• 87727-96-6 (2R,3R)-3-((E)-(S)-3-Hydroxy-oct-1-enyl)-2-[(Z)-3-(4-methoxy-phenyl)-allyl]-cyclopentanone 
• 87692-36-2 (2R,3R)-3-((E)-(S)-3-Hydroxy-oct-1-enyl)-2-[(E)-3-(4-methoxy-phenyl)-allyl]-cyclopentanone 
• 87727-94-4 (1S,2R,3R)-3-((E)-(S)-3-Hydroxy-oct-1-enyl)-2-[(Z)-3-(4-methoxy-phenyl)-allyl]-cyclopentanol 
• 87692-34-0 (1S,2R,3R)-3-((E)-(S)-3-Hydroxy-oct-1-enyl)-2-[(E)-3-(4-methoxy-phenyl)-allyl]-cyclopentanol 
• 87727-93-3 (1S,2R,3R)-3-[(E)-(S)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-2-[(Z)-3-(4-methoxy-phenyl)-allyl]-cyclopentanol 

Relevant articles and documents

Improving the aqueous stability of prostaglandin E2 and prostaglandin A2 by inclusion complexation with methylated-β-cyclodextrins

-

-

-

Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same

The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

Lipase-catalysed acylation of prostanoids

Natural prostaglandins (PG) F(2α) and E1 as well as (+)-cloprostenol were regioselectively 11-acylated using Novozym 435 as a catalyst and vinyl acetate as an acyl donor. Unlike the above compounds the 15-OH group of PGE2 was also acylated with a significant velocity under the same conditions. The enantiospecificity of the lipase-catalysed 11-acetylation of cloprostenol was established by separate treatment of (+)- and (-)-cloprostenols.